Literature DB >> 19682667

The obesity paradox, weight loss, and coronary disease.

Carl J Lavie1, Richard V Milani, Surya M Artham, Dharmendrakumar A Patel, Hector O Ventura.   

Abstract

PURPOSE: Because obesity is a cardiovascular risk factor but is associated with a more favorable prognosis among cohorts of cardiac patients, we assessed this "obesity paradox" in overweight and obese patients with coronary heart disease enrolled in a cardiac rehabilitation and exercise training (CRET) program, making this assessment in patients classified as overweight/obese using both traditional body mass index (BMI) and percent body fat assessments. Additionally, we assessed the efficacy and safety of purposeful weight loss in overweight and obese coronary patients. PATIENTS AND METHODS: We retrospectively studied 529 consecutive CRET patients following major coronary events before and after CRET, and compared baseline and post program data in 393 overweight and obese patients (body mass index [BMI] > or =25 kg/m(2)) divided by median weight change (median=-1.5%; mean +2% vs -5%, respectively). In addition, we assessed 3-year total mortality in various baseline BMI categories as well as compared mortality in those with high baseline percent fat (>25% in men and >35% in women) versus those with low baseline fat.
RESULTS: Following CRET, the overweight and obese with greater weight loss had improvements in BMI (-5%; P <.0001), percent fat (-8%; P <.0001), peak oxygen consumption (+16%; P <.0001), low-density lipoprotein cholesterol (-5%; P <.02), high-density lipoprotein cholesterol (+10%; P <.0001), triglycerides (-17%; P <.0001), C-reactive protein (-40%; P <.0001), and fasting glucose (-4%; P=.02), as well as marked improvements in behavioral factors and quality-of-life scores. Those with lower weight loss had no significant improvements in percent fat, low-density lipoprotein cholesterol, triglycerides, C-reactive protein, and fasting glucose. During 3-year follow-up, overall mortality trended only slightly lower in those with baseline overweightness/obesity who had more weight loss (3.1% vs 5.1%; P=.30). However, total mortality was considerably lower in the baseline overweight/obese (BMI > or =25 kg/m(2)) than in 136 CRET patients with baseline BMI <25 kg/m(2) (4.1% vs 13.2%; P <.001), as well as in those with high baseline fat compared with those with low fat (3.8% vs 10.6%; P <.01).
CONCLUSIONS: Purposeful weight loss with CRET in overweight/obese coronary patients is associated with only a nonsignificant trend for lower mortality but is characterized by marked improvements in obesity indices, exercise capacity, plasma lipids, and inflammation, as well as behavioral factors and quality of life. Although an "obesity paradox" exists using either baseline BMI or baseline percent fat criteria, these results support the safety and potential long-term benefits of purposeful weight loss in overweight and obese patients with coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682667     DOI: 10.1016/j.amjmed.2009.06.006

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  59 in total

1.  Roles of saturated vs. polyunsaturated fat in heart failure survival: not all fats are created equal.

Authors:  Ganesh V Halade; Yu-Fang Jin; Merry L Lindsey
Journal:  Cardiovasc Res       Date:  2011-11-08       Impact factor: 10.787

2.  The obesity paradox: perception vs knowledge.

Authors:  Philip A Ades; Patrick D Savage
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

3.  Body composition and heart failure prevalence and prognosis: getting to the fat of the matter in the "obesity paradox".

Authors:  Carl J Lavie; Richard V Milani; Hector O Ventura; Abel Romero-Corral
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

Review 4.  Polychlorinated biphenyls and links to cardiovascular disease.

Authors:  Jordan T Perkins; Michael C Petriello; Bradley J Newsome; Bernhard Hennig
Journal:  Environ Sci Pollut Res Int       Date:  2015-04-17       Impact factor: 4.223

5.  The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis.

Authors:  Kamyar Kalantar-Zadeh; Elani Streja; Csaba P Kovesdy; Antigone Oreopoulos; Nazanin Noori; Jennie Jing; Allen R Nissenson; Mahesh Krishnan; Joel D Kopple; Rajnish Mehrotra; Stefan D Anker
Journal:  Mayo Clin Proc       Date:  2010-11       Impact factor: 7.616

6.  Physician diagnosis of overweight status predicts attempted and successful weight loss in patients with cardiovascular disease and central obesity.

Authors:  Siddharth Singh; Virend K Somers; Matthew M Clark; Kristin Vickers; Donald D Hensrud; Yoel Korenfeld; Francisco Lopez-Jimenez
Journal:  Am Heart J       Date:  2010-11       Impact factor: 4.749

7.  The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data.

Authors:  R Padwal; F A McAlister; J J V McMurray; M R Cowie; M Rich; S Pocock; K Swedberg; A Maggioni; G Gamble; C Ariti; N Earle; G Whalley; K K Poppe; R N Doughty; A Bayes-Genis
Journal:  Int J Obes (Lond)       Date:  2013-10-31       Impact factor: 5.095

Review 8.  Physical activity, cardiorespiratory fitness, and exercise training in primary and secondary coronary prevention.

Authors:  Damon L Swift; Carl J Lavie; Neil M Johannsen; Ross Arena; Conrad P Earnest; James H O'Keefe; Richard V Milani; Steven N Blair; Timothy S Church
Journal:  Circ J       Date:  2013-01-18       Impact factor: 2.993

Review 9.  Mechanisms of adverse cardiometabolic consequences of obesity.

Authors:  Carlos M Diaz-Melean; Virend K Somers; Juan Pablo Rodriguez-Escudero; Prachi Singh; Ondrej Sochor; Ernesto Manuel Llano; Francisco Lopez-Jimenez
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

10.  Recent trends in weight loss attempts: repeated cross-sectional analyses from the health survey for England.

Authors:  C Piernas; P Aveyard; S A Jebb
Journal:  Int J Obes (Lond)       Date:  2016-08-16       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.